Nymox up 15% on fexapotide triflutate safety data

• Thinly traded micro cap Nymox Pharmaceutical (NASDAQ:NYMX +15.4%) is up on triple normal volume following its announcement of long-term safety data on lead drug fexapotide triflutate (FT). The company says there have been no identifiable risks or serious side effects/adverse events associated with repeated injections of FT.
• Marketing applications in Europe and the U.S. are in process.
• Previously: Nymox Pharma's fexapotide shows long-term benefit in men with low-grade prostate cancer; shares ahead 20% (Jan. 22)